GLP-1 medications are FDA-approved specifically for weight loss for more than half the adult population of the United States. Plan sponsors can take action to manage weight and other cardiodiabesity-related health challenges within their member population.

A report from the Evernorth Research Institute offers insights that can help health plans optimize cancer care.

To create a strong pipeline of early career technology talent, and create equitable opportunities for underrepresented students, Evernorth has partnered with Access Point – a program designed to provide accelerated hands-on technical training and mentorship.

We are taking a thoughtful and comprehensive approach to assessing biosimilar options that considers several factors.

SDOH are shown to contribute as much as 80 percent to a person’s health versus clinical care, which is only 20 percent.

To better understand how socioeconomic disparities impact breast cancer screening and care, the Evernorth Research Institute analyzed claims data of more than 168,000 women covered by commercial health insurance, Medicaid, or Medicare.